Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 41 min ago
Peer-reviewedCC BY 4.0eLife

Molidustat targets a synthetic lethal vulnerability in APC-mutant colorectal cancer through GSTP1 and PHD2 co-inhibition

  1. 1Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom
  2. 2Technische Universität Berlin, Si-M/'Der Simulierte Mensch', a Science Framework of Technische Universität Berlin and Charité – Universitätsmedizin Berlin, Berlin, Germany

Abstract

Mutations in the adenomatous polyposis coli (APC) gene are a defining feature of colorectal cancer (CRC) and impose metabolic and stress adaptation requirements that may create exploitable vulnerabilities. Prolyl hydroxylase domain (PHD) inhibitors have been explored as therapeutic agents in CRC; however, their mechanisms of action and off-target effects remain elusive. Serendipitously, we found that Molidustat, a PHD2 inhibitor, induced cell death in human APC-mutant CRC cells. Ablation of PHD2 alone did not affect cell viability, suggesting an off-target mechanism. Using thermal proteome profiling and chemical proteomics, we identify glutathione S-transferase P1 (GSTP1) as a previously unrecognised off-target of Molidustat and demonstrate direct inhibition of its enzymatic activity. Genetic ablation of PHD2 alone did not phenocopy the cytotoxic effects of Molidustat, whereas combined loss of PHD2 and GSTP1 induced synergistic proteomic changes associated with cell-cycle suppression and apoptotic signalling. Integrated proteomic and metabolomic analyses further revealed energetic and metabolic perturbations specific to simultaneous GSTP1 and PHD2 loss. Consistent with these findings, APC-mutant mouse organoids displayed selective sensitivity to Molidustat that was not reproduced by hydroxylase inhibition alone, supporting a synthetic lethal interaction between GSTP1 and PHD2 in APC-mutant contexts. Together, these results identify a functional interaction between GSTP1 and PHD2 in a subset of CRC and suggest that off-target engagement of GSTP1 contributes to the anti-tumour activity of Molidustat.

Related

  1. A genome-wide computational approach for therapeutic targets identification and synthetic peptide assembly enable rational vaccine design against Arcanobacterium haemolyticum
    Khawaja Fawad Parvez, Farwa Najeeb, Muhammad Umer Khan +6
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textMolecular biology & gene regulationCrossref
  2. Evolution-Informed Viroinformatics Identifies Conserved Immune Targets with Predicted Lower Mutational Vulnerability Across Betacoronaviruses.
    Jamilah Alshammari, Huda A Alqahtani, Rasha Alonaizan +5
    VirusesPeer-reviewedCC BYFull textMolecular biology & gene regulationEurope PMC
  3. CRISPR screens reveal MCT1-driven metabolic escape from SMAD3 inhibition as a therapeutic vulnerability
    Antti Matvere, Grégory Menchon, Laetitia Martinetti +13
    Molecular CancerPeer-reviewedCC BY-NC-ND 4.0Full textMolecular biology & gene regulationHALPMC
  4. 5-Azacytidine Reprograms Colorectal Cancer Cells Toward Senolytic Vulnerability and Enhanced T-Cell-Mediated Cytotoxicity
    Darya A. Lisitsa, Ekaterina D. Kolosova, Natalia A. Budkina +3
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0General biochemistryCrossref
  5. Target-Specific Benchmarking of Potency Prediction on Activity-Cliff Compounds Across 33 Human Protein Targets Using Inhibition Constants
    Mohammed Musallam Mohammed Alamri, Shovonlal Bhowmick, Ritesh P. Bhole +3
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0General biochemistryCrossref
BibTeX
@article{asselborn2026molidustat,
  title = {{Molidustat targets a synthetic lethal vulnerability in APC-mutant colorectal cancer through GSTP1 and PHD2 co-inhibition}},
  author = {Chiara Asselborn and Agata N Makar and Jair G Marques Junior and Aslihan Bastem Akan and Athanasia Yiapanas and Carrie Jennings and Ana Perez-Lopez and Jimi Wills and Asier Unciti-Broceta and Kevin B Myant and Alex von Kriegsheim},
  journal = {eLife},
  year = {2026},
  month = nov,
  doi = {10.7554/elife.110991},
  url = {https://elifesciences.org/articles/110991},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Molidustat targets a synthetic lethal vulnerability in APC-mutant colorectal cancer through GSTP1 and PHD2 co-inhibition
AU  - Chiara Asselborn
AU  - Agata N Makar
AU  - Jair G Marques Junior
AU  - Aslihan Bastem Akan
AU  - Athanasia Yiapanas
AU  - Carrie Jennings
AU  - Ana Perez-Lopez
AU  - Jimi Wills
AU  - Asier Unciti-Broceta
AU  - Kevin B Myant
AU  - Alex von Kriegsheim
PY  - 2026
DA  - 2026/11/10
JO  - eLife
DO  - 10.7554/elife.110991
UR  - https://elifesciences.org/articles/110991
AB  - Mutations in the adenomatous polyposis coli (APC) gene are a defining feature of colorectal cancer (CRC) and impose metabolic and stress adaptation requirements that may create exploitable vulnerabilities. Prolyl hydroxylase domain (PHD) inhibitors have been explored as therapeutic agents in CRC; however, their mechanisms of action and off-target effects remain elusive. Serendipitously, we found that Molidustat, a PHD2 inhibitor, induced cell death in human APC-mutant CRC cells. Ablation of PHD2 alone did not affect cell viability, suggesting an off-target mechanism. Using thermal proteome profiling and chemical proteomics, we identify glutathione S-transferase P1 (GSTP1) as a previously unrecognised off-target of Molidustat and demonstrate direct inhibition of its enzymatic activity. Genetic ablation of PHD2 alone did not phenocopy the cytotoxic effects of Molidustat, whereas combined loss of PHD2 and GSTP1 induced synergistic proteomic changes associated with cell-cycle suppression and apoptotic signalling. Integrated proteomic and metabolomic analyses further revealed energetic and metabolic perturbations specific to simultaneous GSTP1 and PHD2 loss. Consistent with these findings, APC-mutant mouse organoids displayed selective sensitivity to Molidustat that was not reproduced by hydroxylase inhibition alone, supporting a synthetic lethal interaction between GSTP1 and PHD2 in APC-mutant contexts. Together, these results identify a functional interaction between GSTP1 and PHD2 in a subset of CRC and suggest that off-target engagement of GSTP1 contributes to the anti-tumour activity of Molidustat.
SN  - 2050-084X
ER  -